Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Prazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.55 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.55 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.55 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.55 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.55 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.55 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.55 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.55 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.55 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.55 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.55 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.55 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.55 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.55 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 6/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prazepam SCHEMBL78272 | 0.89 | OPRK1 (0.69) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| Prazepam SCHEMBL29565880 | 0.89 | OPRK1 (0.69) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| Prazepam SCHEMBL7617057 | 0.82 | OPRK1 (0.60) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| Prazepam SCHEMBL312369 | 0.80 | OPRK1 (0.72) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL5349082 | 0.80 | TP53 (0.84) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL13352310 | 0.79 | TP53 (0.58) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL11770839 | 0.78 | TP53 (0.69) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| SCHEMBL5355886 | 0.78 | OPRK1 (0.73) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| Prazepam SCHEMBL18321926 | 0.77 | OPRK1 (0.54) | TP53OPRK1NR1I2ADORA3OPRM1 | |
| Prazepam SCHEMBL7537961 | 0.77 | LMNA (0.64) | TP53OPRK1NR1I2ADORA3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421266-B2 | Safety of pseudoephedrine drug products | PISGAH LABORATORIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-8859622-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | PISGAH LABORATORIES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8575151-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | Pisgah National Laboratories, Inc. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8334322-B1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | Pisgah Laboratories, LLC (US) | 2012-12-18 | — | — | US | disclosed |
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | PISGAH LABORATORIES, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293695-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | SLC6A2, SLC18A2, SLC6A3 | GABRP 644/4885GABRD 1764/4885GABRA1 531/4885 |
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | SORD, ABCB11, ABCB1 | GABRP 446/4885GABRD 562/4885GABRA1 632/4885 |
| US-20090259039-A1 | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance | SLC18A2, SLC18A1, SLC6A2 | GABRP 378/4885GABRD 1229/4885GABRA1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.